Abstract Search

ea0022p159 | Cardiovascular endocrinology and lipid metabolism | ECE2010

Changes in serum concentrations and tissue expression of fibroblast growth factor-21 during and after elective major cardiac surgery

Drapalova Jana , Kotulak Tomas , Kopecky Petr , Mraz Milos , Riha Hynek , Blaha Jan , Kramar Petr , Netuka Ivan , Maly Jan , Kremen Jaromir , Kotrlikova Eva , Svacina Stepan , Haluzik Martin

Introduction: Fibroblast growth factor-21 (FGF-21) is a novel regulator of glucose and lipid metabolism and insulin sensitivity. Possible role of FGF-21 in the development of insulin resistance in critically ill patients has not been studied yet.Objective: To study the changes in FGF21 production and adipose tissue and skeletal muscle FGF-21 mRNA gene expression in cardiac surgery patients.Methods: Sixteen patients (16 men, aged 66...

0 shares

ea0063gp139 | Obesity | ECE2019

Prediction of clinically significant weight loss with Gelesis100 in the GLOW study as early as 8 weeks post-treatment

Luzi Livio , Raben Anne , Astrup Arne , Matejkova Erika , Svacina Stepan , Gnessi Lucio , Navas-Carretero Santiago , Martinez J Alfredo , Greenway Frank , Aronne Louis , Apovian Caroline , Kaplan Lee , Hill James , Fujioka Ken , Still Christopher , Sannino Alessandro , Saponaro Cosimo , Calderon Henry , Urban Lorien , Chiquette Elaine , Leider Harry , Ron Eyal , Zohar Yishai , Heshmati Hassan

Introduction: Identification of early responders is widely used in pharmacotherapy for weight loss to minimize unnecessary exposure to risks and unnecessary expenses. Gelesis Loss Of Weight (GLOW; NCT02307279), a multicenter, double-blind, placebo-controlled pivotal study, demonstrated that Gelesis100 offers a compelling new potential approach in the management of overweight and obesity.Objective: A post-hoc area under the curve (AUC) for the receiver op...

0 shares

Endocrine Abstracts

Changes in serum concentrations and tissue expression of fibroblast growth factor-21 during and after elective major cardiac surgery

Prediction of clinically significant weight loss with Gelesis100 in the GLOW study as early as 8 weeks post-treatment

BiosciAbstracts